EA201892479A1 - Compounds of 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole for the treatment of cancer - Google Patents
Compounds of 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole for the treatment of cancerInfo
- Publication number
- EA201892479A1 EA201892479A1 EA201892479A EA201892479A EA201892479A1 EA 201892479 A1 EA201892479 A1 EA 201892479A1 EA 201892479 A EA201892479 A EA 201892479A EA 201892479 A EA201892479 A EA 201892479A EA 201892479 A1 EA201892479 A1 EA 201892479A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- compounds
- indole
- dihydro
- tetrahydropyranylcarbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Данное изобретение относится к некоторым новым соединениям 2,3-дигидро-1H-индола, фармацевтическим композициям, содержащим соединения, и к способам использования соединений для лечения рака, в частности для лечения рака, выбранного из группы, состоящей из меланомы, острого миелоидного лейкоза, хронического лимфоцитарного лейкоза, колоректального рака, рака молочной железы, рака легких, рака яичников, карциномы фаллопиевых труб, первичной перитонеальной карциномы, рака шейки матки, рака желудка, рака печени, рака поджелудочной железы, рака щитовидной железы, глиомы, неходжкинской лимфомы и лимфомы Ходжкина.This invention relates to some new compounds of 2,3-dihydro-1H-indole, pharmaceutical compositions containing the compounds, and to methods of using the compounds for treating cancer, in particular for treating cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, stomach cancer, liver cancer, pancreatic cancer, cancer thyroid gland, glioma, non-Hodgkin lymphoma and Hodgkin lymphoma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348457P | 2016-06-10 | 2016-06-10 | |
| PCT/US2017/035097 WO2017213919A1 (en) | 2016-06-10 | 2017-05-31 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201892479A1 true EA201892479A1 (en) | 2019-07-31 |
| EA037419B1 EA037419B1 (en) | 2021-03-25 |
Family
ID=59031409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892479A EA037419B1 (en) | 2016-06-10 | 2017-05-31 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US9872853B2 (en) |
| EP (1) | EP3468965B1 (en) |
| JP (1) | JP6632746B2 (en) |
| KR (1) | KR102241258B1 (en) |
| CN (1) | CN109641881B (en) |
| AR (1) | AR108586A1 (en) |
| AU (1) | AU2017277833B2 (en) |
| BR (1) | BR112018072872A2 (en) |
| CA (1) | CA3027035C (en) |
| CL (1) | CL2018003543A1 (en) |
| CO (1) | CO2018013251A2 (en) |
| CR (1) | CR20180579A (en) |
| CY (1) | CY1123660T1 (en) |
| DK (1) | DK3468965T3 (en) |
| DO (1) | DOP2018000278A (en) |
| EA (1) | EA037419B1 (en) |
| EC (1) | ECSP19001734A (en) |
| ES (1) | ES2797981T3 (en) |
| HR (1) | HRP20200769T1 (en) |
| HU (1) | HUE050155T2 (en) |
| IL (1) | IL263497B (en) |
| JO (1) | JOP20170131B1 (en) |
| LT (1) | LT3468965T (en) |
| MA (1) | MA45224B1 (en) |
| MD (1) | MD3468965T2 (en) |
| ME (1) | ME03744B (en) |
| MX (1) | MX2018015275A (en) |
| MY (1) | MY197462A (en) |
| NZ (1) | NZ748500A (en) |
| PE (1) | PE20190378A1 (en) |
| PH (1) | PH12018502572A1 (en) |
| PL (1) | PL3468965T3 (en) |
| PT (1) | PT3468965T (en) |
| RS (1) | RS60322B1 (en) |
| SG (1) | SG11201809625RA (en) |
| SI (1) | SI3468965T1 (en) |
| TW (1) | TWI671294B (en) |
| UA (1) | UA122526C2 (en) |
| WO (1) | WO2017213919A1 (en) |
| ZA (1) | ZA201807688B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10179792B2 (en) | 2016-03-07 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| BR112020004112A2 (en) | 2017-08-28 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | hepatitis b antiviral agents |
| WO2019089412A1 (en) * | 2017-11-01 | 2019-05-09 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| EP3727374A4 (en) * | 2017-12-21 | 2021-11-10 | Merck Patent GmbH | Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2020036837A1 (en) * | 2018-08-17 | 2020-02-20 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors |
| UY38383A (en) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | HETEROCYCLES FUNCTIONALIZED AS ANTIVIRAL AGENTS |
| WO2020096871A1 (en) | 2018-11-06 | 2020-05-14 | Merck Sharp & Dohme Corp. | Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors |
| EP3883570A4 (en) | 2018-11-21 | 2022-07-13 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN114105961B (en) * | 2021-12-10 | 2023-09-12 | 海南梵圣生物科技有限公司 | Preparation method of IDO1 inhibitor (LY-3381916) |
| CN114213310B (en) * | 2021-12-31 | 2024-02-23 | 中国药科大学 | Indoline compound and derivative thereof, preparation method, pharmaceutical composition and application |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE467616T1 (en) * | 2003-04-11 | 2010-05-15 | High Point Pharmaceuticals Llc | COMPOUNDS WITH ACTIVITY AT 11BETA-HYDROXASTEROID DEHYDROGENASE |
| DK2559690T3 (en) * | 2005-05-10 | 2016-04-25 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of use thereof |
| US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| CA2713519A1 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Amide derivatives as positive allosteric modulators and methods of use thereof |
| BRPI0915692B8 (en) * | 2008-07-08 | 2021-05-25 | Incyte Corp | compounds derived from 1,2,5-oxadiazoles, their solid form, their composition, as well as their uses |
| NO2694640T3 (en) * | 2011-04-15 | 2018-03-17 | ||
| EP2970114B1 (en) * | 2013-03-15 | 2019-05-15 | Bristol-Myers Squibb Company | Ido inhibitors |
| DK3125883T3 (en) * | 2014-04-04 | 2020-10-19 | Iomet Pharma Ltd | CONTENTS DERIVATIVES FOR USE IN MEDICINE |
| UY36391A (en) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO1), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US10898483B2 (en) * | 2015-12-23 | 2021-01-26 | Moonshot Pharma Llc | Methods for inducing an immune response by promoting premature termination codon read-through |
-
2017
- 2017-05-24 JO JOP/2017/0131A patent/JOP20170131B1/en active
- 2017-05-24 AR ARP170101413A patent/AR108586A1/en unknown
- 2017-05-25 TW TW106117300A patent/TWI671294B/en not_active IP Right Cessation
- 2017-05-31 LT LTEP17728990.7T patent/LT3468965T/en unknown
- 2017-05-31 CA CA3027035A patent/CA3027035C/en active Active
- 2017-05-31 MA MA45224A patent/MA45224B1/en unknown
- 2017-05-31 US US15/609,115 patent/US9872853B2/en active Active
- 2017-05-31 UA UAA201811735A patent/UA122526C2/en unknown
- 2017-05-31 SG SG11201809625RA patent/SG11201809625RA/en unknown
- 2017-05-31 MD MDE20190462T patent/MD3468965T2/en unknown
- 2017-05-31 AU AU2017277833A patent/AU2017277833B2/en not_active Ceased
- 2017-05-31 NZ NZ748500A patent/NZ748500A/en not_active IP Right Cessation
- 2017-05-31 CN CN201780035976.4A patent/CN109641881B/en not_active Expired - Fee Related
- 2017-05-31 EA EA201892479A patent/EA037419B1/en unknown
- 2017-05-31 PT PT177289907T patent/PT3468965T/en unknown
- 2017-05-31 JP JP2018563823A patent/JP6632746B2/en active Active
- 2017-05-31 ME MEP-2020-98A patent/ME03744B/en unknown
- 2017-05-31 PL PL17728990T patent/PL3468965T3/en unknown
- 2017-05-31 HU HUE17728990A patent/HUE050155T2/en unknown
- 2017-05-31 KR KR1020187035215A patent/KR102241258B1/en active IP Right Grant
- 2017-05-31 PE PE2018003199A patent/PE20190378A1/en unknown
- 2017-05-31 DK DK17728990.7T patent/DK3468965T3/en active
- 2017-05-31 MY MYPI2018002369A patent/MY197462A/en unknown
- 2017-05-31 RS RS20200623A patent/RS60322B1/en unknown
- 2017-05-31 CR CR20180579A patent/CR20180579A/en unknown
- 2017-05-31 BR BR112018072872-1A patent/BR112018072872A2/en not_active Application Discontinuation
- 2017-05-31 ES ES17728990T patent/ES2797981T3/en active Active
- 2017-05-31 SI SI201730252T patent/SI3468965T1/en unknown
- 2017-05-31 EP EP17728990.7A patent/EP3468965B1/en active Active
- 2017-05-31 WO PCT/US2017/035097 patent/WO2017213919A1/en unknown
- 2017-05-31 US US16/307,612 patent/US10759786B2/en active Active
- 2017-05-31 MX MX2018015275A patent/MX2018015275A/en unknown
-
2018
- 2018-11-15 ZA ZA2018/07688A patent/ZA201807688B/en unknown
- 2018-12-04 IL IL263497A patent/IL263497B/en active IP Right Grant
- 2018-12-06 PH PH12018502572A patent/PH12018502572A1/en unknown
- 2018-12-06 CO CONC2018/0013251A patent/CO2018013251A2/en unknown
- 2018-12-10 DO DO2018000278A patent/DOP2018000278A/en unknown
- 2018-12-10 CL CL2018003543A patent/CL2018003543A1/en unknown
-
2019
- 2019-01-09 EC ECSENADI20191734A patent/ECSP19001734A/en unknown
-
2020
- 2020-05-12 HR HRP20200769TT patent/HRP20200769T1/en unknown
- 2020-06-05 CY CY20201100508T patent/CY1123660T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201892479A1 (en) | Compounds of 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole for the treatment of cancer | |
| EA202092590A1 (en) | PYRIDAZINONES AS PARP7 INHIBITORS | |
| MX2023000889A (en) | Bcma antibodies and use of same to treat cancer and immunological disorders. | |
| ZA201906832B (en) | Novel psma-binding agents and uses thereof | |
| EA201891344A1 (en) | NEW APONEL RECEPTOR AGONISTS AND APPLICATION METHODS | |
| EA201890857A1 (en) | COMPOUNDS APPLICABLE AS IMMUNOMODULATORS | |
| EA201891200A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201691361A1 (en) | ANTIBODIES TO LAG-3 FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANT TUMORS | |
| EA201892229A1 (en) | SUBSTITUTED AMINOPURIN COMPOUNDS CONTAINING THEIR COMPOSITIONS AND TREATMENT METHODS WITH THEIR APPLICATION | |
| TR201901445T4 (en) | Il2rbeta / common gamma chain antibodies. | |
| UY36419A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | |
| MX2019001471A (en) | Anti-siglec-7 antibodies for the treatment of cancer. | |
| EA201790543A1 (en) | METHODS OF TREATING DISEASES OR DISORDERS USING COMPOSITIONS FOR ORAL APPLICATION CONTAINING CYTIDINE ANALOGUES IN COMBINATION WITH MONOCLONAL ANTIBODY TO PD1 OR PDL1 | |
| EA201692513A1 (en) | INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1 | |
| EA201991480A1 (en) | BESPECIFIC MOLECULES RELATING TO ANTI-FNO-RELATING APOPTOSIS LIGAND RECEPTOR 2 AND ANTI-CADHERIN 17 FOR TREATMENT OF CANCER | |
| EA201792169A1 (en) | 5'-SUBSTITUTED NUCLEOSIDE CONNECTIONS | |
| EA201790376A1 (en) | INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1 | |
| CL2015001990A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith. | |
| EA201890858A1 (en) | 2,4-DIHYDROXINICOTINAMIDES AS APJ AGONISTS | |
| EA201790502A1 (en) | HYSTON DIMETHYLASE INHIBITORS | |
| EA201792287A1 (en) | METHODS OF TREATING CANCER | |
| WO2019023315A3 (en) | Rac inhibitors | |
| MX2016016507A (en) | Compositions and methods for treating cancers. | |
| EA201992315A1 (en) | COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER | |
| MX2018001315A (en) | Fucosidase inhibitors. |